Dr. Johnson is the scientific mind steering the course of Glycyx's research and development. His extensive background in pharmacology and his role in the early development of the now widely-used drug, rifaximin, demonstrate a history of tangible success in drug development. As a co-founder of Salix Pharmaceuticals, he has brought 13 NDAs to market, Dr. Johnson's expertise in gastrointestinal pharmacology and his experience in bringing drugs from conception to market are vital to Glycyx's success. His leadership in the development of axelopran positions the company at the forefront of addressing Opioid-Induced Immunotherapy Failure.